Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942160 · ClinicalTrials.gov registry record · Phase 2
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT02942160: Completed Phase 2 study, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
NCT02942160 is a Phase 2 study that has completed, run by Endo USA Inc., a Keenova Therapeutics Company. The registered enrollment target is 259 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942160, a Phase 2 study, has completed, sponsored by Endo USA Inc., a Keenova Therapeutics Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
Primary Outcome
Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) and Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) is a 5-level scale ranging from "0" (None) to "4" (Severe). A 2-level composite responder is a participant that received EN3835 with a reduction (decrease in score) in severity of at least 2-levels from baseline on both the CR-PCSS and the PR-PCSS at a particular visit. Observation Phase is defined as the time period from Screening to the first treatment date o
Interventions
- BIOLOGICAL Collagenase Clostridium Histolyticum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2018-06-14 |
| Phase | Phase 2 |
What the finished NCT02942160 record still lists
NCT02942160 is an interventional study that assigns participants to a tested intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 1 intervention - of which Collagenase Clostridium Histolyticum is the first listed.
NCT02942160 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02942160 about?
NCT02942160 is a clinical study titled "EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)". A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).
What is the current status of trial NCT02942160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2016-10-05. Estimated completion is 2018-06-14.
What interventions are being tested in trial NCT02942160?
The interventions under investigation include: Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT02942160?
This trial is sponsored by Endo USA Inc., a Keenova Therapeutics Company, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02942160's enrollment target sits among peer trials
259 212th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI